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Smythea* 
a Dept of Biomedical Science, University of Sheffield, Sheffield, UK, S10 2TN 
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Drug resistance to platinum chemotherapeutics targeting DNA often involves abrogation of apoptosis, and has emerged as a significant chal-
lenge in modern, non-targeted chemotherapy. Consequently, there is great interest in the anti-cancer properties of metal complexes - particu-
larly those that interact with DNA - and mechanisms of consequent cell death. Herein we compare a parent cytotoxic complex 
[Ru(phen)2(tpphz)]2+ [phen = 1,10-phenanthroline, tpphz = tetrapyridyl [3,2-a:2',3'-c:3'',2''-h:2''',3'''-j] phenazine], with a mononuclear ana-
logue with modified intercalating ligand, [Ru(phen)2(taptp)]2+,[taptp = 4,5,9,18-tetraazaphenanthreno[9,10-b] triphenylene], and two struc-
turally related di-nuclear, tpphz-bridged, heterometallic complexes, RuRe and RuPt. These changes result in a switch from intercalation to 
groove binding DNA interaction, concomitant reduction in cytotoxic potency, but no significant change in relative cytotoxicity toward plati-
num-resistant A2780CIS cancer cells, indicating that DNA interaction mode is not critical for the mechanism of platinum resistance. All vari-
ants exhibited a light-switch effect, which for the first time, was exploited to investigate timing of cell death by live cell microscopy. Surprising-
ly, cell death occurred rapidly as a consequence of oncosis, characterized by loss of cytoplasmic volume control, absence of significant mito-
chondrial membrane potential loss, and lack of activation of apoptotic cell death markers. Importantly, a novel, quantitative proteomic analy-
sis of the A2780 cell genome following exposure to either mononuclear complex reveals changes in protein expression associated with global 
cell responses to oxidative stress, and DNA replication/repair cellular pathways. This combination of a multiple targeting modality and induc-
tion of a non-apoptotic death mechanism makes these complexes highly promising chemotherapeutic cytotoxicity leads.   
    Introduction 
The spectacular success of cisplatin as an anticancer therapeutic 
has led to  huge growth in research into the interaction of metal 
complexes with biomolecules. Initial work focussed on PtII-based 
analogues of cisplatin, 1-8 although these studies have broadened 
out to include other metal centres. 9-12 These systems are genotoxic 
as they irreversibly bind to DNA. In the case of cisplatin, its most 
prominent effect is to generate platinated intrastrand lesions 
through coordination at adjacent G-sites, 13-15 triggering DNA 
repair mechanisms 1, 16-17 that ultimately lead to mitochondrial-
mediated apoptosis. Despite a consistent rate of initial responses, 
cisplatin treatment often results in the development of chemo-
resistance, leading ultimately to therapeutic failure. Consequently, 
there is a considerable interest in the development of systems 
which may be used to overcome this challenge.   
As a chemotherapeutic that induces apoptosis, 1, 16-17 cisplatin is 
not unusual, most anti-cancer therapeutics are pro-apoptotic. 18-19 
This has implications for the treatment of therapeutically-resistant 
cancers as mechanisms of intrinsic or acquired chemotherapy 
resistance often involve abrogation of apoptotic pathways. 20-24 
Approximately one third of all solid cancers respond poorly to 
current treatments due to insensitivity to pro-apoptotic signalling. 
25 
The primary cause of most cancer-related mortality, metastasis, 
arises from the avoidance of cell death induced by loss of 
anchorage, or anoikis. 26 Anoikis is a form of apoptosis initiated by 
detachment from the extracellular matrix or neighbouring cells. 27-28 
Consequently, tumour cells that evade apoptosis are not only likely 
to be chemoresistant, but more liable to  survive to metastasize and 
produce secondary tumours. As a result of these issues, molecules 
that induce non-apoptotic cell death29-30 are actively being sought as 
new and effective treatments for therapeutically resistant and 
metastatic cancers. 25, 31-33 
Although cisplatin and its analogues irreversibly bind to DNA, 
research into metal complexes that bind reversibly has also bur-
geoned. A large amount of this work has involved photoactive sys-
tems, 34 and in particular polypyridyl RuII complexes. 35-37 Much 
attention was prompted by the properties of the original DNA 
light-switch system, [Ru(bpy)2(dppz)]2+ (bpy = 2,2Õ-bipyridine, 
dppz = dipyrido[2,3-a:3¢,2¢-c]phenazine); 38-39 this complex is non-
emissive in aqueous solutions but displays bright, RuII®dppz 
3MLCT-based luminescence on intercalation into DNA. Although 
the parent complex is not taken up into cells, localization into the 
nucleus and binding to chromatin has been accomplished through 
changes in ancillary ligands40-41 or attachment to targeting moie-
ties.42 
Most of these studies have been aimed at creating live-cell imag-
ing probes, however some recent reports have shown that specific 
RuII(dppz) derivatives can act as novel sensitizers for photodynam-
ic therapy. 43-45 In related work, we have been investigating the bio-
logical properties of RuII(tpphz) systems, where tpphz =  tetra-
pyridyl [3,2-a:2',3'-c:3'',2''-h:2''',3'''-j] phenazine.46  
Previous studies have investigated the DNA binding properties 
of both mono- and dinuclear Ru(tpphz) complexes. For example, it 
is established that  [Ru(bpy)2(tpphz)]2+ binds to duplex DNA with 
affinities comparable to its dppz analogues 47 and although it acts as 
a DNA light-switch, its emission output can be Òswitched offÓ by 
 2 
metal ion binding at its second coordination site. 48 While studies 
on its dinuclear analogue [{Ru(bpy)2}2(tpphz)]4+ have revealed 
that it displays a light-switch effect when it binds to DNA despite 
interacting though non-intercalative groove binding. 49 Our work 
has led to the identification of [{Ru(phen)2}2(tpphz)]4+ (phen = 
1,10-phenanthroline) as a luminescent probe for nuclear DNA in 
live cells. This DNA groove-binding complex, which is photostable 
and displays low toxicity even after 24 hours exposure, is spontane-
ously taken up by cells through an energy-dependent, non-
endocytic mechanism. 
 
Scheme 1. Complexes investigated in this study 
Like the dinuclear system, the mononuclear intercalating com-
plex [Ru(phen)2(tpphz)]2+, , is taken up by cells, and 
shows cellular DNA binding;50 however, it also displays cytotoxicity 
comparable to cisplatin and its potency is retained even in cisplatin-
resistant cell lines. 50 Unsurprisingly given its mode of interaction 
with DNA, , interferes with DNA replication51  and it is a 
potent radiosensitizer. 51 Yet, a more detailed understanding of the 
cellular responses it induces, including cell death mechanisms, is 
still to be developed. Given the lack of cross-resistance and distinct-
ly different DNA binding mode of  compared to cispla-
tin, we decided to investigate the biological action of this system in 
more detail and compare its properties to three new structurally 
related complexes,  and the dinuclear complexes  
and  Ð Scheme 1. 
Results and Discussion 
 
Complexes  50 and  52 were synthesized 
through previously reported methods. We initially attempted to 
synthesize complex  by reacting  with 
Pt(DMSO)2Cl2; however, this produced intractable mixtures. It 
was found that the target complex could be successfully synthesized 
through the direct reaction of  with K2(PtCl4).  Using a 
similar method  can be synthesized through the direct reac-
tion of  with Re(CO)5Cl. 
By comparison with the previously reported spectrum of 
, 53 and with the aid of COSY, the 1H-NMR spectra of all 
the other complexes were assigned. For example: in the spectrum 
of complex  the signals at 10.12 ppm and 9.60 ppm which 
were assigned to protons a and c of the tppz ligand correlate with a 
signal at the center of a complex multiplet found at 8.34-8.17 ppm, 
which is assigned to proton b. A similar pattern of connectivities is 
found for the other tpphz based signals d, e, and f. The phenanthro-
line-based signals can also be assigned through similar cross-peak 
patterns Ð Figure 1. 
It should be noted that even in a coordinating solvent such as 
MeCN, no changes in the spectra of  and  were ob-
served, suggesting that in these conditions, the chlorido ligands on 
the Pt and Re centres of these complexes do not undergo ligand 
exchange. This is consistent with many previous studies 33, 54-55 in 
which chlorido extraction from these inert metal centers is only 
accomplished using Ag+. 56 As it is known that the 1H NMR spec-
trum of  is concentration-dependent due to stacking of 
the tppz unit, the effect of concentration on the spectra of the two 
new dinuclear complexes was also investigated.   
 
Figure 1. Details of the 1H NMR COSY spectrum of [RuRe](PF6)3 in 
MeCN 
While complex  shows distinctive changes that are con-
sistent with the previously reported stacking interactions involving 
the tpphz ligand, 56 Ru  displays no concentration dependent 
shifts in its 1H NMR spectrum (Figure S1). This difference is at-
tributed to the different coordination geometries of the metal cen-
ters attached to the RuII(tpphz) fragment. As the PtII unit is square 
planar, and essentially linear, stacking between individual  
complexes, involving extended tpphz moieties, is still possible. In 
contrast,  units do not stack upon one another as the 3-D 
structure of the octahedral ReI unit prevents such interactions; an 
observation that is consistent with previous reports on the NMR 
spectra of homo-dinuclear RuII complexes such as 
[{Ru(bpy)2}2(tpphz)]4+. 
 
D  
The complexes were converted to water-soluble chloride salts for 
their biophysical and cellular studies. The cell-free DNA binding 
properties of RuPt and RuRe were studied in aqueous buffer solu-
tions.  
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Figure 2. Increase in luminescence of [RuPt]Cl2 on addition of calf 
thymus DNA (lex = 450 nm). Inset: derived binding curve from these 
data. 
 
To aid comparison, corresponding data for  and 
 and the dinuclear complex [{Ru(bpy)2}2(tpphz)]4+ in 
the same conditions were also reassessed. As expected, all the com-
plexes displayed light-switch effects on the addition of CT-DNA, as 
illustrated by the response of  shown in Figure 2. 
Fits of these data to the non-cooperative McGhee-von Hippel 
model yielded the binding parameters summarized in Table 1. The 
estimated binding affinity of  is very similar to that pre-
viously reported values, whereas the value for is higher 
than that for  the closely related complex [Ru(bpy)2(taptp)]2+,  
but the two sets of data were collected using different conditions 
and fitted to different models. A comparison of the binding affini-
ties of  and  with [{Ru(bpy)2}2(tpphz)]4+ reveals some 
interesting differences. 
As shown before, the homo-dinuclear system displays a very high 
affinity for duplex DNA (>107 M-1), consistent with the fact that it 
is a confirmed groove binder. Site sizes less than 1 bp for the het-
ero-dinuclear complexes suggest that these complexes also display 
external stacking modes and imply that the estimated Kb values are 
actually lower limits for affinities. 
T  Summary of DNA binding parameters for all complexes.a 
Complex Kb (´106 M-1) Site Size (b.p.)
 
 0.45 1.8 
 7.2 1.7 
 80 0.8 
 1.6 0.8 
[{Ru(bpy)2}2(tpphz)]4+   45 2.2 
a As chloride salts in 5 mM Tris, 25 mM NaCl, pH 7.4. 
 
Strikingly, the estimates for  indicate a binding affinity ap-
proaching 108 M-1, a figure that is extremely high for a single-site 
binding, non-threading, metal complex. In contrast,  displays 
a lower Kb comparable to the figures for  and . 
The higher binding affinity of  compared to  and 
[{Ru(bpy)2}2(tpphz)]4+ is striking, as this complex is less charged 
than the other two dinuclear systems; therefore electrostatics will 
make a lower contribution to the interaction with DNA. 57To gain a 
second estimate of Kb, through a non-optical method equilibrium 
dialysis experiments were also carried out and these led to a calcu-
lated Kb for , of 2.8 x107 M-1, which is in good agreement with 
luminescence based data (Figure S2). Nevertheless, as the NMR 
data described above also show that  aggregates and it is 
known that such interactions can greatly affect estimates of binding 
parameters, 58 this figure must be treated with some caution. On the 
other hand, the reduced binding affinity of  compared to the 
other dinuclear groove binders is also notable.59 In our previous 
studies on RuII systems we have found that, due to specific unfa-
vourable contacts within a groove, even a single functional group 
can reduce DNA binding affinities by several orders of magnitude. 
Given that the square planar PtII moiety of  does not negative-
ly affect binding, it seems that the axial ligands of the ReI(CO)3Cl 
unit of  must be responsible for similarly unfavourable groove 
contacts. 
Although  is an established intercalator,46,47 viscosity 
experiments showed that, unlike the well-known intercalator eth-
idium bromide (which induces large positive viscosity changes), 
progressive addition of each of the three new complexes to buffered 
CT-DNA solutions produce virtually no change in relative viscosity 
- Figure 3.  
 
Figure 3. Changes in the relative viscosity (η/ η0)1/3 of an aqueous 
DNA solution after addition of Ru(tpphz), Ru(taptp), RuRe and RuPt 
(all chloride salts). The intercalator ethidium bromide (EtBr) and 
groove-binder Hoechst 33258 are included for comparative purposes. 
As these effects are almost identical to the minor groove binder 
Hoechst 33258, these data confirm that both mononuclear 
 and the new dinuclear complexes  and  are 
also groove binders. These observations are consistent with our 
recent report on a mononuclear, tetracationic, derivative of 
;  this complex, in which the uncoordinated site of the 
tpphz ligand has been converted into a dicationic ethylene-
bipyridyldiylium unit, also groove binds to duplex DNA,60 confirm-
ing previous reports that even fused and rigid polycyclic aromatic 
systems like tpphz derivatives can groove bind if their curvature and 
charge distribution is complementary to that of duplex DNA. 61-63 
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To determine whether the new complexes have potential as anti-
cancer agents, and, if so, which structural properties maximize their 
potency, and any ability to counteract cisplatin-resistance, they 
were tested for cytotoxicity against the human ovarian carcinoma 
cell line A2780 and its cisplatin-resistant daughter cell line 
A2780CIS. Cells were exposed to a concentration gradient of each 
complex for 48 h and resultant cell population viabilities were as-
sessed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay  and these data were com-
pared with the anticancer drug cisplatin, and   as con-
trols. IC50 values, the concentration at which cell viability is reduced 
by 50% compared to untreated control, were determined from the 
curves of percentage cell viability against complex concentration. 
Figure 4 shows the cell viability curves produced by this analysis, 
and the IC50 values for each complex are summarized in Table 2. In 
addition, the resistance factor, RF, the ratio 
IC50(A2780CIS)/IC50(A2780), was determined for each complex.   
 
 
Figure 4.   Cell viability data for A2780 and A2780CIS cells 
treated with the indicated complexes and cisplatin (Cis), analysed 
by MTT assay (experiments performed in triplicate and data dis-
played as an average of at least 2 independent experiments 
 
The RF for cisplatin, an eleven-fold reduction in potency be-
tween A2780CIS compared to A2780, is in good agreement with 
literature values.50 Consistent with our previous reports,50 
 displays cytotoxicity with potency equivalent to cispla-
tin in A2780 cells, but importantly, this compound remains equipo-
tent against A2780CIS cells (Figure 4A). Although  is 
not as potent as , it still displays significant cytotoxicity 
against A2780 cells, and importantly shows no loss of potency in 
A2780CIS cells (Figure 4B). Interestingly, despite incorporating a 
PtII centre,  displays the lowest overall cytotoxicity in both 
A2780 and A2780CIS cell lines - although, like , there is 
no cross-resistance observed in cisplatin-resistant cells.  has 
the second highest potency against A2780 cells, but Ð apart from 
cisplatin itself Ð displays the highest RF of this series of compounds. 
T    
 
Resistance factor (RF) defined as IC50(A2780CIS)/IC50(A2780).  
Given the striking absence of cross-resistance with either 
 or  in the A2780 ovarian cancer model sys-
tem, these two complexes were selected for further study and com-
parison to cisplatin cytoxicity in additional cancer cell models 
(MCF7 breast carcinoma, T24 bladder carcinoma as well as two 
non-cancer cell lines (HEK293 human embryonic kidney cells and 
MRC5 lung fibroblasts).  The cell viability curves are shown in 
Figure S3, and the IC50 values for each complex are summarized in 
Figure S4. In all cases IC50 values obtained with cisplatin were 
consistent with literature values. 65-67  
Interestingly in MCF7 cells,  was found to be significantly 
more cytotoxic (IC50 = 7.2 µM) than cisplatin (IC50 = 19.2 µM) and 
substantially more effective than  (IC50 >100 µM) Bladder 
carcinoma is known to be particular sensitive to platinum based drugs 
68. Consistent with this, T24 bladder cancer cells were most sensitive to 
cisplatin (IC50 = 1.5 !M) with reasonable toxicity observed with 
R  (IC50 = 7.6 !M). As with MCF7cells, T24 cells were rela-
tively insensitive to The MRC5 non-cancerous cell line 
showed similar sensitivities to both and cisplatin (IC50 = 
15.8 µM and 11.3 µM respectively) while once again, sensitivity to 
Ru(tpphz) was not detected over the concentrations examined. In 
addition, both complexes are only active in the HEK293 non-tumor 
line at concentrations that are over two orders of magnitude higher 
than the values for even the therapeutically resistant ovarian cancer line 
(Figure S4). Overall, this study suggests  and  
exhibit the most promising cytotoxic properties as both display low 
IC50 values and RFs, and markedly lower cytotoxic activity against non-
cancer cells. Next the cellular uptake of each complex was investigated. 
 
Although each mononuclear species displays intrinsic cytotoxici-
ty and lacks cross-resistance with cisplatin, there is a significant 
difference in potency between them in A2780 cell lines, despite 
similarity in structure (Figure 4, Table 2). This could be the conse-
quence of two possibilities Ð either cytotoxicity reflects differential 
uptake efficiency 5, 69-70 with the same intracellular mode of action 
 5 
for  both complexes, or each complex utilizes a distinct intracellular 
mechanism to provoke cell death. 
To examine whether the differing cytotoxicity profiles could be 
attributed to differences in uptake, inductively coupled plasma 
mass spectrometry (ICP-MS) was used to determine the relative 
cellular accumulation of all 4 complexes in either A2780 or 
A2780CIS cells, by measuring the ruthenium content of extracts 
derived from cells after 1hour exposure (Figure S5).  Cells were 
treated with all complexes at equipotent (IC50 values; Table 2) 
concentrations and results are expressed as the molar intracellular 
Ru concentration. 
Interestingly, treatment of A2780 cells with either  or 
 resulted in comparable intracellular content after 1 hour 
(46 and 61 µM respectively), whilst both and  were 
actually internalized at slightly higher concentrations (103 µM and 
83 µM respectively). Nevertheless, all compounds showed substan-
tial cellular accumulation, from ~9-fold (RuRe) to 20-fold 
(Ru(tpphz) above the medium concentration. As expected, cellular 
accumulation of all compounds in A2780CIS cells was significantly 
reduced, consistent with the notion that A2780CIS cell have ac-
quired significant efflux capability. 71 In A2780 cells, the extent of 
accumulation of each complex followed the order >  
> > , which does not correlate with the order of 
anti-proliferative capability ( . 
Similarly, the efficacy of accumulation in A2780CIS cells was in the 
order > > >  with anti-proliferative 
capacity being ( . Taken to-
gether, these data show that differential uptake is not responsible 
for the differences in cytotoxic potency seen across this series of 
compounds. In addition, the efficiency of accumulation of all com-
pounds was significantly reduced in A2780CIS cells compared with 
the parental A2780 cells. Significantly this suggests that complex 
accumulation is not a limiting factor in the determination of cyto-
toxic potency. 
 
C  
Pt-based complexes primarily target DNA, and provoke a geno-
toxic response, which induces cell death predominantly via apopto-
sis. 1 Other metal-based systems induce a range of cytotoxic re-
sponses, disrupting mitochondrial as well as genomic integrity 72-76, 
in addition to oxidative stress, 77-79 to bring about apoptotic cell 
death. Cell morphology changes characteristic of apoptosis include 
membrane blebbing, cell shrinkage, and pyknosis. 29 Some metal 
based systems have been reported to induce either non-specific 
necrosis, or ischemic cell death or oncosis. 75, 80 
Live cell imaging, using brightfield and fluorescence microscopy, 
was initially used to investigate mechanisms of cell death induced 
by each complex. To observe cell death in a period of hours, a com-
plex concentration greater than the determined IC50 values, 50 μM, 
was chosen. Images were recorded at 2 minute intervals, with ob-
servations initiated after treatment in a live-cell microscopy cham-
ber equilibrated to 37 ¼C in an atmosphere containing 5% CO2. 
Following treatment with each of the complexes, both A2780 
and A2780CIS cells were observed to undergo a variable degree of 
rounding, manifested as an apparent decrease in cell circumference, 
followed by a period of dramatic swelling, with changes that were 
consistent with oncosis (Figure S6) rather than apoptosis. 
 
Figure 5. Morphology and luminescent imaging of live A2780 and 
A2780CIS cells following exposure to 50 µM RuRe for the indicated 
times. 
These observations were quantified by manual measurements of 
cell diameter using ImageJ software (Figure S7). Simultaneously, 
luminescence intensity was monitored by imaging using an excita-
tion wavelength of 405 nm and emission over the range 640 Ð 800 
nm. Strikingly, cell swelling was followed by a rapid increase in 
nuclear luminescence, as loss of cell and organelle integrity, associ-
ated with cell death, facilitated unfettered access of each complex to 
chromosomal DNA, giving rise to a light-switch effect (Figure 5). 
We utilized this effect as an indicator of timing of cell death, and 
determined the time duration required to induce cell death for each 
of the complexes in individual A2780 and A2780CIS cells (Figure 
6). 
In A2780 cells, death-associated increase in luminescence was 
observed within 180 mins, with little difference observed between 
,  or , (mean time to death 103 +/- 5, 96 
+/- 5, 110 +/- 5 mins respectively) while death in -treated 
cells  occurred more slowly (mean time to death 138 +/- 9 mins). 
Interestingly, the variability in -treated cells reflected an in-
crease in the dependence of time to death on initial cell size (Figure 
S8), prior to swelling. In A2780CIS cells, the mean time to death 
was shorter compared to A2780 cells for all 4 compounds 
( : 73 +/- 5 min,  74 +/- 5 min,  103 +/- 
13 min, : 107 +/- 6 min). Again, with treated cells, an 
increased dependence on initial cell size was observed (Figure S8). 
Taken together, these cellular studies indicate that the mononu-
clear complexes  and  display the most prom-
ising properties as therapeutic leads to address intrinsic or acquired 
platinum treatment resistance, as they display an excellent combi-
nation of higher potency, and low cross-resistance with cisplatin. In 
contrast, the dinuclear  and  complexes display lower 
overall potency or higher cross-tolerance. 
Apoptosis is known to involve the initiation of a proteolytic en-
zyme cascade, following mitochondrial release of cytochrome C 
and loss of membrane potential, in which the caspase family of 
proteases are activated. 29 These induce the specific cleavage of a 
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Figure 6. (A & B) Time elapsed until cell death of individual A2780 
(A) and (B) A2780CIS cells exposed to the indicated compounds 
(50µM). Data indicate mean +/- SEM for 10 cells in each treatment.  
 
number of intracellular protein targets including the DNA repair 
protein PARP-1 (Poly(ADP-ribose) polymerase-1). 29 In order to 
establish whether either  or  activate any apop-
totic response in cell populations,  immunoblotting of whole cell 
lysates was undertaken to detect the apoptotic-specific cleaved 
form of PARP-1 in A2780CIS cells treated with either  
or  at an equipotent (IC50) concentration. No evidence 
of apoptosis was observed in either  and -
treated cells, in contrast to cisplatin treatment of either A2780CIS 
or HeLa cell lines (Figure 7). 
Consistent with this observation, measurements of mitochondri-
al membrane potential in A2780CIS cells exposed to either 
 or  for up to 24 hours at IC50 concentrations 
showed little or no significant change compared with untreated 
control cells, in contrast to the mitochondrial poison FCCP (Fig-
ure S9). 
Taken together, the observations outlined above indicate that 
cell death induced by  and  occurs via oncosis. 
Given the promising therapeutic characteristics of  and 
 we sought to gain further insights into their mechanism 
of action and biomolecular targeting through a proteomic study. 
 
 
 
Figure 7. Absence of PARP cleavage by Ru(tpphz) or Ru(taptp). Im-
munoblotting analysis of lysates derived from A2780CIS cells treated 
with either Ru(tpphz), Ru(taptp) or cisplatin (Lanes 1-4) or Hela cells 
treated with cisplatin alone for the presence of cleaved PARP with α-
tubulin as loading control. In A2780CIS cells, IC50 values (were used 
for Ru(tpphz) and Ru(taptp), and IC25 values for cisplatin (determined 
as described in SI). HeLa cells were treated with cisplatin (5 µM) for 
48 h. 
 
P  
Systematic studies into the effect of biologically active metal 
complexes on the proteome are rare. A number of initial reports 
involved cisplatin and its derivatives; for example, mechanisms of 
acquired cisplatin resistance in ovarian cancer, 81  neuroblastoma, 82 
and cervix squamous cell carcinoma cells have been explored. 83 
More recently, studies on ruthenium-based systems have emerged. 
A proteomic study on the antimetastatic agents trans-
[RuCl4(DMSO)(imidazole)]- and [Ru(η6-toluene)Cl2 (PTA)] 
(RAPTA-T), (PTA = 1,3,5-triaza- 7-phosphaadamantane) re-
vealed that they induce changes in protein expression that are very 
different to cisplatin. 84 Further studies on RAPTA, including an 
affinity precipitation assay, revealed putative protein targets in-
volved in cell cycle regulation, cell growth, histone modification, 
and ribosomal processing. 85 
As  and  are kinetically inert reversible DNA 
binders, this suggests that their therapeutic action is distinctly dif-
ferent to both classical genotoxins like cisplatin and antimetastatics 
such as RAPTA-T, both of which contain kinetically labile chlorido 
ligands that are an intrinsic to their function. To explore this issue 
in more depth, the effect of treatment with  and 
  on protein expression levels in A2780CIS cells was un-
dertaken using Stable Isotope Labelling by Amino Acids in Cell 
Culture (SILAC), 86 combined with LC-MS/MS analysis using a 
hybrid Orbitrap Elite mass spectrometer. This approach has the 
advantage of providing accurate determinations of change in pro-
tein expression by ratiometric determination of multiple peptides 
derived from any one protein. Additionally, it provides the oppor-
tunity to undertake subsequent informatics analyses to identify 
protein functional groups, thus providing insight into the global 
cellular response to any one compound. 
This approach facilitates a direct comparison of individual pro-
tein expression levels following exposure of cells to a specific treat-
ment compared to untreated control. Here, cells were grown either 
in standard culture medium containing isotopically normal 
(ÒlightÓ) amino acids or medium containing Òheavy,Ó 13C6, and 15N4 
labelled, arginine and lysine. After treatment of the ÒlightÓ cell pop-
ulation with the compound of interest, and control treatment of the 
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isotopically ÒheavyÓ cells, derived cell lysates are combined in a 1:1 
mass ratio, and the mixture denatured and fractionated by SDS-
PAGE.   
 
Figure 8. Analysis of protein expression change following treatment of 
A2780CIS cells for 48 hours with respective IC50 concentrations of (A) 
 and (B)  Data are presented as the log ratio of 
expression in the presence versus the absence of the indicated 
compound plotted against intensity Based Absolute Quantitation for 
each protein. Significant changes (down-regulation: red, up-regulation 
green) in protein expression are annotated using Uniprot protein IDs. 
(C)Bio-informatics analysis of gene products whose expression is 
altered in A and B. 
Proteins are proteolytically fragmented in situ, and resultant pep-
tides extracted and subjected to LC-MS/MS (see SI). Changes in 
protein expression may be determined by ratiometric determina-
tion of signal intensity in pairs of chemically identical ÒlightÓ and 
ÒheavyÓ peptides, revealing up- or down-regulation of specific pro-
teins on treatment. Analysis of data was carried out as described in 
SI, using MaxQuant and Pegasus software. 87 
A2780CIS cells were left untreated, or treated with either 
 or  at a concentration close to respective IC50 
value ( : 4.4 µM; : 13 µM) of each complex for 
48 hours. Following cell lysis, protein content determination, nor-
malization, purification, in-gel digest, analysis and data processing, 
a list of identified proteins and the ratio of their expression between 
untreated and treated populations was generated. Over 3400 dis-
tinct proteins were identified and ratios of abundance in the ab-
sence and presence of each complex determined as described 
above. This generated 54 hits that met the selection criteria de-
scribed in S.I. For each complex, the extent to which each protein 
was up- or down- regulated following exposure is shown in Figure 
8A and B, and is expressed as the log2 [ratio of light/heavy isotopic 
species] (X-axis) plotted against intensity-based absolute quantifi-
cation (IBAQ;Y-axis), which provides an indicator of the relative 
abundance of each identified protein. The summary of protein 
sequence and function included in Supplementary Figure 10 is 
from the open access resource UniProt. 
In the case of cells treated with  the abundance of 42 
proteins was significantly altered, with 32 up-regulated, and 10 
proteins down-regulated. Of the 42 proteins identified, a significant 
fraction (9) is associated with the processes of DNA replication, 
DNA repair, or checkpoint signaling associated with replication 
stress (Fig 8C). Three of these are histone proteins, the levels of 
which are increased in cells undertaking or arrested in S phase.88 
Eight proteins are directly involved in a number of DNA repair 
processes. MMS19 is an essential component of the CIA (cytosolic 
iron-sulphur protein assembly complex), that mediates incorpora-
tion of iron-sulphur cluster in proteins involved in DNA metabo-
lism including the helicases ERCC2/XPD, required for nucleotide 
excision repair, FANCJ, involved in DNA double strand break re-
pair, and RTEL1, required for telomere maintenance and genome 
stability. 89 METTL3 encodes the catalytic subunit of N6-
adenosine-methyltransferase, which methylates adenosine residues 
in RNA, and is absolutely required for the recruitment of DNA 
polymerase κ to nuclear sites of DNA damage for nucleotide exci-
sion repair and trans-lesional synthesis. 90 UBE2V2 is a non-
canonical variant  ubiquitin ligase-like protein that, as a heterodi-
mer with UBE2N, catalyzes the synthesis of poly-ubiquitin chains  
that generate a location signal for the consequent recruitment of 
DNA repair proteins. 91 VRK1 is a nucleosomal associated protein 
kinase that phosphorylates the DNA damage marker histone H2AX 
as an essential step in the formation of nuclear DNA repair foci. 92 
Strikingly, HMGA2 is a member of high-mobility group A non-
histone chromatin proteins that are involved in both activation of 
the mismatch repair response and base excision repair. 93 This pro-
tein group has been implicated in the cellular response to platinated 
DNA adducts:. 94 HMGA2 is required for the activation of the 
ATR/Chk1 checkpoint signalling system in response to the pres-
ence of guanine adducts 95 and consequently, suppression of apop-
tosis. 96 Elevated expression of SETD1A facilitates the binding of 
cyclin K 97 a cell-cycle regulated transcription factor, and binding is 
essential for the up-regulation of multiple genes involved in the 
DNA damage response. 98 
Taken together these data are consistent with the known DNA 
binding properties of  in vitro 50 (Figure 3)  as well as its 
effect on DNA replication in vivo. 51 Importantly, they provide  
additional detailed insight into the nature of the cellular DNA dam-
age response to and suggest that, in addition to replica-
tion fork stalling,  binding of  to DNA in vivo provokes a 
requirement for both nucleotide excision and DNA mismatch re-
pair pathways. 
Unlike cisplatin and its derivatives, a significant number of 
Ru(II) based systems that target DNA are, catalytically inert; fur-
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thermore, a number of the systems that show significant cytoxicity 
in human cancer cells have been reported to generate reactive oxy-
gen species.  99-102 
Levels of reactive oxygen species that surpass cellular anti-
oxidant defenses result in oxidative stress, where the capacity of 
cells to repair bio-molecular oxidation of proteins, lipids, RNA and 
DNA is exceeded, resulting in persistent damage. Multiple cellular 
processes are triggered in response to oxidative stress. These in-
clude modulation of oxygen-sensitive signaling pathways, such as 
the nutrient and stress sensor, mTORC1, 103 the NFkB transcrip-
tion factor family,104 the hypoxia-inducible factor (HIF-1) tran-
scription system, 105 in addition to checkpoint signaling pathways 
described above. These pathways are responsible for metabolic 
reprogramming 105 to increase anti-oxidant levels, activation of 
DNA repair 106-107, activation of the endoplasmic reticulum unfold-
ed protein response (UPR), 108 elevation of  organelle regeneration 
via autophagy - the process of damaged cell content recycling 109 - 
and  response to lipid peroxidation.110 
Interestingly the largest group of proteins whose expression level 
was altered in response to  treatment are associated with 
cellular or mitochondrial responses to reactive oxygen species and 
oxidative stress.  13 proteins associated with the cellular response to 
oxidative stress were up-regulated in response to cellular exposure 
to  in A2780CIS cells. Up-regulation of the ubiquitin 
carboxy-terminal hydrolyase USP19 as well as C1QTNF3, 111 me-
diates both the ROS-stimulated stabilization of the transcription 
factor HIF (hypoxia inducible factor) 1 112 as well as the ERAD 
(endoplasmic-reticulum-associated degradation) or UPR (unfold-
ed protein response) system.113-114 USP19 cellular function in con-
junction with UCHL1, another ubiquitin hydrolyase, results in 
HIF1-mediated metabolic reprogramming to increase levels of the 
anti-oxidant reduced glutathione (GSH). 115 Sec62 up-regulation 
facilitates resolution of the unfolded protein response by selectively 
delivering ER components to the autolysosomal/autophagy system 
for clearance and or recycling. Hamartin (TSC1) expression to-
gether with Tsc2 down-regulates mTORC1 which is a central regu-
lator of  autophagic flux. Reduced mTorc1 activity facilitates induc-
tion and nucleation of phagophores, which in turn leads to elevated 
autophagic flux. 109 VTA1 in association with components of the 
ESCRT complex 116 including VPS28, is involved in the multivesic-
ular body-mediated protein transport in autophagy.117 RPS6KA3 
encodes ribosomal S6 protein kinase, which is an essential effector 
of mTORC signaling. 103 
Elevated levels of the NF-kB transcription factor family compo-
nent RelA plays a role in cell growth and survival in response to 
oxidative stress, by increasing transcription of genes involved in 
reducing levels of ROS. 118 Although its precise function is un-
known, RPUSD2, a member of the pseudourididine synthase fami-
ly, is a known target of NFkB. 119 TCOF1 encodes Treacle, a nucle-
osomal protein that controls and regulates ribosome biogenesis, the 
expression of which has been shown to be regulated by oxidative 
stress. 120 MMACHC/CblC is a recently identified molecular chap-
erone and decynase responsible for maintaining intracellular levels 
of cobalamin (vitamin B12) which in turn acts to protect against 
oxidative stress,121-122 while ALDH16A1 encodes an aldehyde dehy-
drogenase which acts as an aldehyde scavenger in response to cellu-
lar lipid peroxidation 123. Increased expression of the intermediate 
filament protein Nestin is known to confer protection against oxi-
dative stress. 124 Given the central role of mitochondria in both 
producers of ROS and and targets of oxidative damage, up-
regulation of a number of mitochondrial-specific ribosomal pro-
teins is consistent with a requirement for newly synthesized mito-
chondrial proteins during periods of elevated autophagic flux. 125 
Significantly fewer proteins showed significant up-regulation or 
down-regulation when cells were exposed to . The reason 
for this is not yet clear although it may be a consequence of its re-
duced potency and the duration of cellular exposure, resulting in 
fewer significant changes in protein expression levels. Despite this, 
categories of proteins affected by (  were broadly similar to 
that of  and consistent changes in expression levels of 
several proteins (C1QTNF3, UCHL1 and HIST1H1D) were ob-
served for both compounds. Of note, treatment of cells with 
(  resulted in altered expression of an additional protein 
(PPP2R4) associated with the DNA damage response. 126 Never-
theless, taken together it seems that both complexes provoke very 
similar cellular responses. Although the mode of DNA binding by 
each of the two complexes is different, they both appear to provoke 
a DNA damage response, as judged by proteomic analysis.   This is 
not surprising as both intercalating agents such as doxorubicin, 127 
as well as groove-binding compounds including Hoechst 33342, 128 
are known to induce DNA damage by interfering with the progres-
sion of the replisome in S phase, as well as preventing efficient 
DNA repair. 127, 128   
A pictorial summary and comparison of the cellular processes af-
fected by treatment with and is shown in 
Figure 8C. 
Conclusions 
Despite being reported almost three decades ago, therapeutic 
leads based on the RuII(dppz) DNA light-switch complex that are 
intrinsically cytotoxic and nuclear targeting are almost non-
existent.  
Chao and co-workers have demonstrated that a cyclometallated 
mono-cationic derivative of the parent complex does localize with-
in the nucleus and is potently cytotoxic through disruption of tran-
scription 129; however, this complex induces classical apoptosis and 
so will not be active in therapeutically resistant cancer in which 
apoptotic pathways have been abrogated. The MacDonnell group 
have demonstrated that dinuclear RuII complexes containing rigid, 
extended redox-active, bridging ligands are cytotoxic through a 
mechanism that involves the generation of reactive oxygen species, 
even in hypoxic conditions. 130 However these systems are not in-
trinsically luminescent and again only induce apoptosis. 131 
The induction of oncotic cell death by this group of Ru complex-
es is novel and unexpected. It is notable that the toxic stress in-
duced by these complexes does not result in the destruction, via 
caspase-mediated proteolysis,  of the enzyme PARP which plays a 
major role in the cellular response both to direct DNA damage in 
addition to that caused by the generation of reactive oxygen spe-
cies. 132 PARP acts to modify target proteins via the synthesis and 
covalent attachment of polymeric adenosine ribose chains.  Im-
portantly significant PARP activation is known to deplete the cellu-
lar pool of the source of ADP ribose, NAD 133 which in turn results 
in oncotic cell death. 134 Future work will establish whether that is 
the mechanism of Ru complex-induced oncosis in this system.    
The systems described herein offer a unique combination of nu-
clear targeting, a DNA light-switch effect, and the capability of 
inducing non-apoptotic cell death. Interestingly the effects induced 
by these systems are not solely dependent on their uptake concen-
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trations, as they retain potency in a cell line known to possess an 
increased efficiency in drug efflux.  
In particular, the mononuclear complexes,  and the 
newly reported ), display a highly promising spectrum of 
properties.  potently blocks the proliferation of ovarian 
carcinoma cell lines with a potency similar to that of the cisplatin, 
which remains a frontline treatment for ovarian cancer. 135 Im-
portantly, it does not show cross-resistance in cells that have devel-
oped resistance to cisplatin, and it induces cell death via a mecha-
nism distinct from apoptosis, which may often be abrogated in 
tumors.  It exhibits lower levels of toxicity than cisplatin in non-
cancer model cell lines. Interestingly, it exhibits much lower poten-
cy against tested bladder and breast carcinoma cell lines. As both 
A2780 and MCF7 cells both retain wild-type p53, while T24 cells 
have a p53 mutant genotype, it is clear that p53 genotype cannot 
explain the differential potency of R  
The activity profile of against MRC5 fibroblasts is no 
more cytotoxic than cisplatin and it is largely ineffective against 
HEK293 cells. As with it shows no cross-resistance in 
platinum-resistant ovarian carcinoma.   However, it is slightly more 
potent than cisplatin in breast carcinoma cells.  Cisplatin plays an 
important role in adjuvant treatment of breast carcinoma after sur-
gery, 136 in patients with inherited forms of breast/ovarian cancer 
syndrome arising from BRCA1 mutations 137 as well as following 
the onset of metastases. 138 It follows that may have 
promise in these settings following emergence of platinum re-
sistance  
In the first proteomic study involving kinetically inert ruthenium 
complexes, we found that these mononuclear complexes induce 
protein expression changes that are indicative of both DNA dam-
age and oxidative stress responses. This first observation is con-
sistent with previous studies confirming that binding 
directly stalls DNA replication forks, 51 however the up-regulation 
of proteins associated with oxidative stress suggest the complexes 
have a second mode of action.  Although the complexes described 
by MacDonnell and coworkers are also cytotoxic through oxidative 
stress they contain ligands that Ð unlike tpphz  131Ð are themselves 
redox active in biological conditions. Given this fact, and the differ-
ent death mechanisms induced by the two classes of complexes, an 
involvement of a similar mechanism for and 
can be discounted. 
As therapeutic regimes displaying more than one mechanism of 
action offer great potential in the treatment of multigenic diseases 
such as cancer and are less susceptible to conventional resistance 
mechanisms, 139 and R  offer great potential as 
metal based anticancer therapeutic leads. Further studies will focus 
on a more detailed analysis of the mode of action. For example, 
although it appears that DNA processing is disrupted by the com-
plexes, details of any sequence or structurally specific binding tar-
gets - and the initial molecular events that lead to oxidative stress - 
still need to be delineated. A deeper understanding of these mecha-
nisms will facilitate the synthesis of derivatives that enhance such 
effects and such studies will form the basis of future reports. 
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